Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial
Listen to this summary
This phase II trial aimed to evaluate the efficacy and safety of ivonescimab combined with gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer (aBTC). The study found a promising objective response rate of 66.7% and a median overall survival of 16.8 months, suggesting that this regimen may be a viable option for treatment-naive patients with unresectable aBTC. Additionally, the research identified MAP2K7 as a potential biomarker for resistance, which could inform future therapeutic strategies.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of hepatology
View all →Jul 11, 2026 · Journal of hepatology
Surveillance of patients at risk of liver cancer: Expert opinions
Jul 8, 2026 · Journal of hepatology
Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease
Jul 6, 2026 · Journal of hepatology
Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort
Jul 5, 2026 · Journal of hepatology
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study
Jul 1, 2026 · Journal of hepatology
Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration
Jul 1, 2026 · Journal of hepatology
Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk
More in Internal Medicine
View all →Jul 11, 2026 · Journal of addiction medicine
Multiple Substance Use Disorders From Adolescence to Midlife
Jul 11, 2026 · American heart journal
Antegrade dissection and re-entry versus retrograde strategy in chronic total occlusion percutaneous coronary intervention: Rationale and design of the ADRENALINE randomized study
Jul 11, 2026 · Mayo Clinic proceedings
Embedding Ethics Into Decision-Making Capacity Assessment:An EHR-Enabled Systemwide Approach
Jul 11, 2026 · American heart journal
Integrative assessment of high-sensitivity C-reactive protein and lipid levels in predicting 20-year atherosclerotic cardiovascular disease risk, in a Mediterranean population: The ATTICA study (2002-2022)
Jul 11, 2026 · American heart journal
Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: a descriptive compatibility analysis
Jul 11, 2026 · Journal of cardiac failure
An abbreviated exercise right heart catheterization protocol for the diagnosis of heart failure with preserved ejection fraction
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
